This series of studies was designed to assess in normal volunteers the relationships between various doses (5, 10, 20, 40, 80, and 120 mg) of the orally active angiotensin II antagonist losartan (DuP 753, MK-954) and their inhibitory effect on the pressure response to a given bolus of angiotensin I or II. It was found that the maximal inhibitory effect was reached with a dose of 80 mg. The minimal dose necessary for maximal efficacy would therefore be expected to be between 40 and 80 mg. The effect lasted for more than 24 h and was related almost exclusively to the circulating levels of the active metabolite EXP3174. It remains to be demonstrated in hypertensive patients that the same dose relationship holds for the antihypertensive effect,...
The renin-angiotensin system is a major contributor to the pathophysiology of cardiovascular disease...
Background. The purpose of the present study was to assess the inhibitory effect of DuP 753, an oral...
New approaches to renin-angiotensin blockade: The successful use of angiotensin converting enzyme (A...
This series of studies was designed to assess in normal volunteers the relationships between various...
We assessed the inhibitory effect of DuP 753, an orally active angiotensin II receptor antagonist, o...
This study was conducted to assess the pharmacologic properties of the new orally active angiotensin...
INTRODUCTION: The evaluation of a new drug in normotensive volunteers provides important pharmacodyn...
We assessed the inhibitory effect of DuP 753, an orally active angiotensin II receptor antagonist, o...
We assessed the inhibitory effect of DuP 753, an orally active angiotensin II receptor antagonist, o...
BACKGROUND: Acute blockade of the renin-angiotensin system with the parenterally active angiotensin ...
BACKGROUND. The purpose of the present study was to assess the inhibitory effect of DuP 753, an oral...
BACKGROUND. The purpose of the present study was to assess the inhibitory effect of DuP 753, an oral...
It is difficult to establish dose-response relationships for ACE inhibitors in patients with hyperte...
We investigated the tolerability and angiotensin II antagonist activity of oral DuP 532 in healthy m...
Use of angiotensin (Ang) II AT1 receptor antagonists for treatment of hypertension is rapidly increa...
The renin-angiotensin system is a major contributor to the pathophysiology of cardiovascular disease...
Background. The purpose of the present study was to assess the inhibitory effect of DuP 753, an oral...
New approaches to renin-angiotensin blockade: The successful use of angiotensin converting enzyme (A...
This series of studies was designed to assess in normal volunteers the relationships between various...
We assessed the inhibitory effect of DuP 753, an orally active angiotensin II receptor antagonist, o...
This study was conducted to assess the pharmacologic properties of the new orally active angiotensin...
INTRODUCTION: The evaluation of a new drug in normotensive volunteers provides important pharmacodyn...
We assessed the inhibitory effect of DuP 753, an orally active angiotensin II receptor antagonist, o...
We assessed the inhibitory effect of DuP 753, an orally active angiotensin II receptor antagonist, o...
BACKGROUND: Acute blockade of the renin-angiotensin system with the parenterally active angiotensin ...
BACKGROUND. The purpose of the present study was to assess the inhibitory effect of DuP 753, an oral...
BACKGROUND. The purpose of the present study was to assess the inhibitory effect of DuP 753, an oral...
It is difficult to establish dose-response relationships for ACE inhibitors in patients with hyperte...
We investigated the tolerability and angiotensin II antagonist activity of oral DuP 532 in healthy m...
Use of angiotensin (Ang) II AT1 receptor antagonists for treatment of hypertension is rapidly increa...
The renin-angiotensin system is a major contributor to the pathophysiology of cardiovascular disease...
Background. The purpose of the present study was to assess the inhibitory effect of DuP 753, an oral...
New approaches to renin-angiotensin blockade: The successful use of angiotensin converting enzyme (A...